The stock of Immunomedics, Inc. (NASDAQ:IMMU) hit a new 52-week high and has $22.91 target or 8.00% above today’s $21.21 share price. The 5 months bullish chart indicates low risk for the $3.55B company. The 1-year high was reported on May, 17 by Barchart.com. If the $22.91 price target is reached, the company will be worth $283.92M more. The stock increased 8.71% or $1.7 during the last trading session, reaching $21.21. About 4.29 million shares traded or 126.67% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has risen 117.70% since May 17, 2017 and is uptrending. It has outperformed by 106.15% the S&P500.
Among 3 analysts covering Victoria Oil Gas PLC (LON:VOG), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Victoria Oil Gas PLC had 16 analyst reports since July 23, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, November 6 by Beaufort Securities. As per Friday, April 8, the company rating was maintained by Beaufort Securities. Beaufort Securities maintained the shares of VOG in report on Wednesday, April 20 with “Speculative Buy” rating. The stock has “Speculative Buy” rating by Beaufort Securities on Tuesday, March 1. The rating was maintained by Beaufort Securities with “Speculative Buy” on Friday, January 29. As per Friday, February 19, the company rating was maintained by Beaufort Securities. On Wednesday, June 1 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. The stock of Victoria Oil & Gas Plc (LON:VOG) has “Buy” rating given on Wednesday, November 18 by Numis Securities. The firm has “Buy” rating given on Friday, May 26 by GMP Securities. The stock of Victoria Oil & Gas Plc (LON:VOG) earned “House Stock” rating by Shore Capital on Thursday, August 18. See Victoria Oil & Gas Plc (LON:VOG) latest ratings:
02/01/2018 Broker: GMP Securities Rating: Buy Maintain
Investors sentiment decreased to 1.07 in 2017 Q4. Its down 0.58, from 1.65 in 2017Q3. It is negative, as 27 investors sold Immunomedics, Inc. shares while 44 reduced holdings. 29 funds opened positions while 47 raised stakes. 117.18 million shares or 4.91% more from 111.69 million shares in 2017Q3 were reported. Metropolitan Life stated it has 0.01% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Ameriprise Fincl owns 600,639 shares. Massmutual Co Fsb Adv accumulated 39 shares. Tower Capital Llc (Trc) has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 149 shares. Schwab Charles Invest reported 517,259 shares. Eam Lc reported 131,382 shares. Point72 Asset Ltd Partnership invested 0.03% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Blackrock Inc owns 9.06 million shares or 0.01% of their US portfolio. Venbio Select Advisor Ltd holds 16.83% or 16.06M shares in its portfolio. Hussman Strategic holds 50,000 shares or 0.23% of its portfolio. Noven Financial Grp Incorporated Inc invested in 12,000 shares or 0.11% of the stock. Hightower Lc reported 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). 8,214 were accumulated by Ameritas Investment Prtn Incorporated. Meeder Asset reported 107 shares or 0% of all its holdings. Alps Advsrs has 0.02% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 168,456 shares.
More notable recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Nasdaq.com which released: “Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast …” on May 16, 2018, also Streetinsider.com with their article: “Immunomedics’ (IMMU) option implied volatility into ASCO” published on May 17, 2018, Seekingalpha.com published: “Reader Inquiry: Is There Further Upside In Immunomedics?” on April 23, 2018. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) were released by: Streetinsider.com and their article: “Pre-Open Movers 05/17: (WWE) (LOXO) (NTES) Higher; (JNCE) (JCP) (ACXM) Lower (more…)” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Immunomedics, Inc. (IMMU) CEO Michael Pehl on Q3 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.
Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics has $16 highest and $1.50 lowest target. $15.50’s average target is -26.92% below currents $21.21 stock price. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with “Buy” rating in Wednesday, December 6 report. Jefferies downgraded Immunomedics, Inc. (NASDAQ:IMMU) rating on Wednesday, July 29. Jefferies has “Hold” rating and $2 target. The rating was downgraded by Wells Fargo to “Market Perform” on Friday, December 4. The rating was maintained by Jefferies on Wednesday, December 6 with “Buy”. Cowen & Co maintained it with “Buy” rating and $15.0 target in Wednesday, August 16 report. The rating was maintained by Jefferies on Tuesday, March 15 with “Hold”. Jefferies upgraded it to “Buy” rating and $5 target in Friday, May 6 report. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Market Perform” rating given on Tuesday, June 21 by Wells Fargo. Jefferies maintained it with “Buy” rating and $900 target in Friday, June 9 report. The stock has “Buy” rating by Cowen & Co on Monday, July 24.
Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on August, 15. They expect $-0.15 EPS, up 40.00% or $0.10 from last year’s $-0.25 per share. After $-0.14 actual EPS reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts 7.14% negative EPS growth.
Since February 28, 2018, it had 0 insider purchases, and 1 insider sale for $2.05 million activity. GOLDENBERG DAVID M had sold 117,729 shares worth $2.05 million.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $3.55 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.